SAN DIEGO , Dec. 06, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech, ” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, today announced that its ophthalmic analysis tear based solutions were featured in leading scientific media environments including Eyes On 2023 and Ophthalmology Times.

Both interviews were conducted with Dr. Rob Sambursky , president of global commercialization partner Verséa Ophthalmics, LLC (“Verséa”). Dr . Sambursky spoke with Brittany J. McMurren , OD, during Eyes on 2023’s interview series at the event’s corporate exhibit hall. In a separate media opportunity, Doctor Sambursky spoke with David Hutton associated with Ophthalmology Times.

The recorded interview conversations provide viewers with further detail into the benefits and science behind AXIM’s newly commercialized proprietary tear dependent diagnostic tests for ocular surface disease patients. In both, Dr. Sambursky discusses the launch of Verséa in to the eye care space with the introduction associated with AXIM’s tear based, quantitative assays.

The Eyes On 2023 job interview can be viewed HERE, and Ophthalmology Times interview can be viewed RIGHT HERE.

In the particular Eyes upon 2023 job interview, Dr . Sambursky notes that while osmolarity testing is currently taking place with ocular surface illness patients, the rapid new tear centered tests offered by the two companies are complementary to those existing tests plus enhance a clinician’s ability to manage treatment in the more personalized way. In the case of the Lactoferrin test, it enables clinicians to measure levels of Lactoferrin in the point-of-care, an industry first, and make therapy decisions within an expedited manner. For instance, he highlights that should a patient show a Lactoferrin deficiency, this would suggest that the patient has an aqueous-deficient dry eye condition, allowing for more targeted therapies by physicians. He also notes that the tests can be repeated over the course of treatment associated with the patient in order to judge whether the treatment is stabilizing Lactoferrin as it should be.

In both interviews, Dr. Sambursky highlights that will Verséa is offering the AXIM IgE assay, which will be specifically designed to diagnose allergic conjunctivitis. Allergic conjunctivitis is usually commonly misdiagnosed as dry eye condition or viral conjunctivitis, which is an important distinction for clinicians in prescribing the particular appropriate treatment and a major differentiator of AXIM’s diagnostic solutions. Additionally , he highlights that Verséa plus AXIM are usually in the process of developing additional assays such as the MMP-9 quantitative rapid lateral flow test, which AXIM aims to bring to market in the second quarter of 2023.

“We continue to be honored to work with such renowned professionals at Verséa including Doctor. Sambursky, ” said John Huemoeller III, CEO associated with AXIM Biotechnologies . “Not only do they fully understand the science at the rear of our technology, but they are able to easily and clearly convey our innovative options to clinicians and business professionals alike. We are excited to continue to work with them on the commercialization of our two FDA-cleared assays, as well as on the advancement of new assays like the MMP-9. ”

Doctor Sambursky , President of Verséa Ophthalmics, LLC , said, “It was the pleasure in order to speak with this kind of relevant market leading outlets about AXIM and Verséa’s leading diagnostic solutions. AXIM has been a strong development companion and supporting. Verséa’s launch of innovative tear based solutions throughout eyecare. We look forward to furthering our partnership to expand access to our own existing portfolio of differentiated products while developing brand new solutions that will enhance clinicians’ capability to treat patients in the most efficacious ways. ”

For more information on AXIM’s diagnostic solutions or to talk to someone at Verséa about adding these revolutionary solutions to your clinic, please visit:

About AXIM ® Biotechnologies
Founded in 2014, AXIM ® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic assessments. The Company owns two of the only five FDA Cleared Diagnostic tests with regard to Dye Vision Disease. For more information, please visit

About Verséa Holdings, Inc.
Verséa Ophthalmic, LLC (“Verséa”), a subsidiary of Verséa Holdings, Incorporation. headquartered inside Tampa, FL , is definitely a U. S. healthcare company founded by experienced business executives and prominent scientific medical experts, all committed to transforming medical discoveries into applicable health care and wellness solutions that are critical in order to improving patients’ lives. To learn more, visit:

Forward-Looking Statements
The particular statements made by Axim Biotechnologies Inc. , in this press release may be “forward-looking” in nature within the particular meaning associated with Section 27A from the Securities Act of 1933, Section 21E associated with the Investments Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions plus involve a number of risks and uncertainties, many of which are usually beyond the particular control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our analysis candidate will ever become approved for use by the U. S. FDA or even any equivalent foreign regulatory agency. Further, Axim’s vision care diagnostic products which are FDA cleared may not be manufactured in large enough quantities or that third parties along with established attention care physicians will enter into agreements or even purchase through the Company, plus even if the Company’s analysis candidates are successful, they may generate just limited revenue and profits for the particular Company. Various other factors are detailed from time to period in Axim’s SEC reports and filings, including the Annual Report on Form 10-K filed on April 15, 2022 , and other reviews we file with the SEC , which are available at Axim Biotechnologies, Inc. , undertakes simply no obligation to update publicly any forward-looking statements in order to reflect new information, events or circumstances after the particular date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

CONTACT Kyle Porter CMW Media
P. 858-221-8001
[email protected] com

AXIM Corporate
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422

Investor Relations
[email protected] com

Primary Logo


2022 GlobeNewswire, Inc., source Press Releases

Leave a Reply

Your email address will not be published. Required fields are marked *